MAP1LC3C and glioblastoma: MAP1LC3C activity increased significantly in GBM, KIRC, BLCA, BRCA, CESC, COAD, HNSC, KICH, LIHC and LUAD tumour types, but decreased significantly in LUSC, PCPG, PRAD, READ, STAD, THCA and UCEC tumour types (Figure 3A).